NCT07928479
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07928479
Title Neoadjuvant Trastuzumab, Pertuzumab and Zongertinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-5 Study (TRAIN-5)
Acronym TRAIN-5
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors The Netherlands Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD


No variant requirements are available.